SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave is rallying as the company reported a significant revenue beat and raised guidance, highlighting explosive demand for its AI infrastructure despite ongoing concerns regarding cash burn and debt levels. The community is actively debating the sustainability of the company's aggressive capital expenditures, with many bulls pointing to the massive revenue backlog as proof of long-term dominance while vocal bears question the underlying math and profitability.

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas Inc. is currently trending as investors focus on its recent contract win with the Israeli Ministry of Defense, while community discussion remains dominated by anticipation of a short squeeze ahead of Thursday's earnings report. Bulls are actively monitoring key technical levels and institutional buying, betting that strong contract momentum and potential guidance raises will trigger a significant breakout for the stock.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius Group is trending as investors weigh an aggressive short position against strong institutional backing and anticipation for its upcoming earnings release. The community is heavily focused on whether the company's AI infrastructure buildout and new contract prospects will trigger a short squeeze or if current valuation concerns will lead to a pullback.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer shares are trending following a massive earnings beat and aggressive FY27 revenue guidance that significantly topped analyst expectations, fueling intense community debate regarding a potential short squeeze. Investors are aggressively discussing the company's strong order backlog and profitability metrics, while skeptics continue to voice concerns over corporate transparency and lingering market sentiment regarding past investigations.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is trending as investors brace for a critical quarterly financial update and closely monitor the ongoing, event-driven REGAL Phase 3 trial for GPS. The community is actively debating the company's self-imposed quiet period, with many bullish investors interpreting the lack of clinical trial updates as a sign that the 80th survival event has not yet occurred, while anticipating that the company's strong cash position and clinical progress will act as major catalysts.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Dallas, TX.

United States Antimony Corp.

United States Antimony Corp. is facing significant volatility following a major guidance cut and a disappointing quarterly earnings report, which has sparked intense debate among investors about management's performance and the company's long-term defense contracts. While the community remains divided over the CEO's leadership and the impact of Chinese market pricing, many long-term shareholders are maintaining conviction due to the company's role as a sole domestic supplier of critical minerals and potential future government support.

Lumentum Holdings, Inc. engages in the provision of optical and photonic products. It operates through the Cloud and Networking, and Industrial Tech segments. The Cloud and Networking segment refers to a portfolio of optical and photonic components, modules, and subsystems. The Industrial Tech segment includes solid-state lasers, kilowatt-class fiber lasers, ultrafast lasers, diode lasers, and gas lasers. The company was founded in 1979 and is headquartered in San Jose, CA.

Lumentum Holdings Inc

Lumentum Holdings is trending due to a stellar quarterly earnings report, with the community highlighting a strong revenue beat, upward-revised guidance, and a critical role in the accelerating AI data center and optical networking buildout. While the stock has seen significant volatility, investors are actively debating the sustainability of the AI infrastructure rally and the company's competitive position within the optical connectivity supply chain.

Velo3D, Inc. operates as a technology company, which engages in developing and manufacturing metal laser sintering printing machines for 3D printing. Its products include assure system, flow software, sapphire printer & sapphire XC. The company was founded by Benyamin Buller in June 2014 and is headquartered in Fremont, CA.

Velo3D Inc

Velo3D is trending as investors digest a massive new facility expansion and ongoing market speculation regarding its role in the aerospace and defense manufacturing supply chain. The community remains highly active, debating the stock's long-term potential as a critical technology enabler versus short-term volatility driven by institutional short interest and technical consolidation.

Cava Group, Inc. is a holding company, which engages in the category-defining Mediterranean fast-casual restaurant brand, bringing together healthful food and bold, satisfying flavors at scale. It operates through the following segments: CAVA and CAVA Foods. The CAVA segment includes the operations of all company-owned CAVA restaurants. The CAVA Foods segment includes the production of dips and spreads used in CAVA restaurants as well as sales from the consumer-packaged goods (CPG) business. The company was founded by Brett Schulman, Ike Grigoropoulus, Dimitri Moshovitis, and Theodore Xenohristos in 2010 and is headquartered in Washington, DC.

Cava Group Inc

CAVA Group Inc

CAVA Group is trending following a double beat on quarterly earnings and revenue that underscored robust consumer demand and strong traffic growth, leading to an initial stock jump. While investors are optimistic about the company's aggressive expansion and status as a best-in-breed Mediterranean chain, community discussions remain focused on potential overvaluation concerns and volatility after an early-trading sell-off.

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.

AbCellera Biologics Inc

AbCellera is trending following the announcement of a new T-cell engager collaboration with Vertex Pharmaceuticals, a move the community views as strong validation of the company's antibody discovery platform. Investors are actively discussing the stock's long-term potential ahead of key clinical data readouts for its lead program, ABCL635, while debating the impact of ongoing volatility and institutional partnership activity.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Travere Therapeutics to Participate at Upcoming Investor Conferences

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that company management will participate in the following upcoming investor conferences: Canaccord Genuity's 46th Annual Growth Conference Presenting on Tuesday, August 11, 2026, at 3:00 p.m. ET Wells Fargo 21st Annual Healthcare Conference...

Travere Therapeutics (TVTX) Stock Rallies Over 13% After Hours: Here's What Is Going On

Travere Therapeutics shares surged 13.44% after hours as strong revenue growth and FILSPARI sales gains outweighed earnings concerns.read more...

Travere (TVTX) Reports Q2 Earnings: What Key Metrics Have to Say

While the top- and bottom-line numbers for Travere (TVTX) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Travere Therapeutics (TVTX) Reports Q2 Loss, Beats Revenue Estimates

Travere (TVTX) delivered earnings and revenue surprises of -164.29% and +10.16%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Travere Therapeutics Reports Second Quarter 2026 Financial Results

Travere Therapeutics, Inc. (Nasdaq: TVTX) today reported its second quarter 2026 financial results and provided a corporate update. With an exceptional second quarter, Travere has entered a new chapter of near- and long-term growth, said Eric Dube, Ph.D., president and chief executive officer of...

Travere Therapeutics to Report Second Quarter 2026 Financial Results

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced it will report second quarter 2026 financial results on Tuesday, August 4, 2026, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general...

Kuehn Law Encourages Investors of Travere Therapeutics, Inc. to Contact Law Firm

Kuehn Law Encourages Investors of Travere Therapeutics, Inc. to Contact Law Firm Kuehn Law Encourages Investors of Travere Therapeutics, Inc. to Contact Law Firm PR Newswire NEW YORK, July 27, 2026 NEW YORK, July 27, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is...

Can Novartis' Fabhalta Strengthen Its Nephrology Franchise?

NVS wins full FDA approval for Fabhalta in IgA nephropathy after phase III data shows slower kidney function decline, strengthening its nephrology portfolio.

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on July 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 41,600 shares of its common stock to six new employees, consisting of inducement stock options to purchase...

Travere Therapeutics Announces Planned Retirement of Chief Research Officer in 2027

Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that William Rote, Ph.D., the Companys chief research officer, plans to retire from the Company in February 2027 following 10 years of service. Jula Inrig, M.D., currently chief medical officer and a member of the Companys executive...

$TVTX Q2 '26 Earnings Results & Recap

• Reported GAAP EPS of -$0.37 down -164.29% YoY
• Reported revenue of $169.58M up 48.17% YoY

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm's products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.

Travere Therapeutics Inc

TVTX Stock Slides 6% On Everest Deal, Erases Some Losses As Analyst Sees 49% Upside

Equity

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '26	$0.02	--	--	N/A
Q2 '26	-$0.13	-$0.37	-174.78%	MISSED
Q1 '26	-$0.24	-$0.40	-65.27%	MISSED
Q4 '25	$0.00	$0.03	1171.73%	BEAT
Q3 '25	-$0.30	$0.28	192.20%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q2 '26

Historical Earnings